Description
Unlock comprehensive insights into soluble cytokine receptors in diagnostic samples with our Soluble Cytokine Receptor 14-Plex Panel.
Cytokine receptors are fundamental to cytokine biology, playing critical roles in both normal physiological functions and various pathological conditions across a wide range of diseases. Many of these soluble receptors can specifically inhibit their cytokine ligands, acting as precise antagonists to modulate cytokine activity. The recognition of their role in regulating excessive inflammation and influencing immune responses has led to significant research into their potential as immunotherapeutic agents.
Applications in Research and Diagnostics
Use this test to identify relevant therapy targets, determine disease mechanisms, and diagnose or monitor the following conditions associated with immune regulation, inflammation, and cancer:
- Autoimmune and Inflammatory Diseases: Assess chronic inflammatory and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE), and multiple sclerosis, where elevated levels of soluble receptors like sIL-1RI, sIL-1RII, sIL-2Rα, sIL-4R, and sIL-6R can indicate ongoing inflammation and immune activation.
- Chronic Inflammatory Diseases: Monitor chronic inflammatory conditions like inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), and chronic kidney disease (CKD), where soluble receptors such as sIL-6R, sgp130, sRAGE, sTNFRI, and sTNFRII reflect the inflammatory state and tissue damage.
- Cancer: Evaluate tumor burden, progression, and response to therapy in various cancers including lymphoma, colorectal cancer, and lung cancer. Soluble receptors like sCD30, sEGFR, sVEGFR1, sVEGFR2, and sVEGFR3 serve as biomarkers for tumor growth, angiogenesis, and immune modulation.
- Cardiovascular Diseases: Assess cardiovascular conditions such as atherosclerosis, heart failure, and hypertension, where elevated levels of soluble receptors like sVEGFR1, sVEGFR2, sVEGFR3, and sRAGE can indicate endothelial dysfunction and vascular inflammation.
- Metabolic Disorders: Investigate metabolic syndrome, diabetes, and obesity, where soluble receptors such as sIL-6R, sTNFRI, sTNFRII, and sRAGE provide insights into the inflammatory and metabolic disturbances associated with these conditions.
- Infectious Diseases: Monitor immune response and inflammation in infectious diseases such as sepsis, HIV, and tuberculosis, where soluble receptors like sIL-1RI, sIL-1RII, sIL-2Rα, sTNFRI, and sTNFRII help assess the severity of infection and the body’s immune response.
- Pulmonary Diseases: Evaluate chronic lung diseases such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD), where soluble receptors like sVEGFR1, sVEGFR2, sVEGFR3, and sRAGE indicate lung tissue remodeling and inflammation.
- Allergic Diseases: Diagnose and monitor allergic conditions such as asthma, atopic dermatitis, and allergic rhinitis, where soluble receptors like sIL-4R and sIL-2Rα reflect Th2-mediated immune responses.
Key Features:
- Comprehensive Biomarker Coverage: Provides a detailed analysis of 14 key biomarkers, including key biomarkers such as sCD30, sIL-6R, and sVEGFR2, ensuring a thorough diagnostic approach.
- CLIA Certified for Clinical Use: As a CLIA certified laboratory, we provide a panel that meets the highest standards of accuracy and reliability for clinical diagnostics.
- Versatility: Use this test when identifying relevant therapy targets, mechanism of disease is unknown, arthritis, macrophage activation syndrome (MAS), Hemophagocytic lymphohistiocytosis (HLH), sepsis / toxic shock, necrotizing fasciitis, admitted meningitis, admitted pneumonia, Kawasaki syndrome, prolonged or periodic fever, severe or chronic inflammation, organ dysfunction.
- Sample Flexibility: Reference intervals are available for PLASMA-EDTA and CSF samples.
- Affordable Assay Services: We offer some of the most affordable assay services available, making advanced diagnostics accessible for clinical applications.
Discover the power of precision with our Soluble Cytokine Receptor 14-Plex Panel, expertly designed for the Luminex® 200™ platform. This cutting-edge technology enables the simultaneous detection of multiple biomarkers from a minimal single sample, delivering comprehensive insights with unmatched efficiency.
Swift Turnaround Time
Trust us for a swift and reliable experience. We pride ourselves on a rapid turnaround time, with results typically delivered within 5 business days of receiving your specimen and payment. With our commitment to precision and efficiency, you can count on us to provide the insights you need, promptly and accurately.
Regulated Tests: Ensuring Quality and Accuracy
The LDT (Lab Developed Test) designation highlights that our tests are regulated by the Centers for Medicare & Medicaid Services (CMS) under CLIA, ensuring they meet stringent quality and accuracy standards. Unlike commercially distributed tests, which undergo FDA approval, our LDTs are developed and validated within our laboratory to provide specialized and reliable diagnostic insights tailored to your needs. This distinction underscores our commitment to maintaining the highest standards in testing and personalized care. Eve Technologies is certified by the Centers for Medicare & Medicaid Services (CMS) as a High Complexity International Laboratory under the Clinical Laboratory Improvement Amendments (CLIA), specializing in Diagnostic Immunology with a subspecialty in General Immunology (CLIA# 99D2283230). Additionally, we hold a clinical and public health laboratory license with the California Department of Public Health (COS-90013367). Our certification underscores our commitment to rigorous standards.
Clinicians: Please check with your State Agency to determine if additional licensure or registration requirements may apply.
! The interpretation of these test results should be correlated with clinical findings and other diagnostic tests. Biomarker levels can vary due to many biological, physiological, and diurnal factors; their clinical significance must be assessed by a qualified healthcare professional. This information is not intended to be used as the sole basis for diagnosis or treatment decisions. ​